Company Filing History:
Years Active: 2024
Title: Fangliang Zhang: Innovator in Immunotherapeutic Fusion Proteins
Introduction
Fangliang Zhang is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of biotechnology, particularly in the development of fusion proteins for immunotherapeutic applications. His innovative work has the potential to enhance cancer treatment strategies.
Latest Patents
Fangliang Zhang holds a patent for a "Fusion protein dimer using antibody Fc region as backbone and use thereof." This invention involves a fusion protein dimer that utilizes an antibody Fc region as its backbone, comprising two polypeptide chains. The first polypeptide chain includes a first antibody Fc region and one or more single-domain antibodies fused to it. The second polypeptide chain contains a second antibody Fc region and one or more single-domain antibodies fused to it as well. Additionally, these chains may include a cytokine fused to the Fc region, enhancing the therapeutic potential of the fusion protein. This innovation not only increases the activity of single-domain antibodies but also significantly improves the biological activity of cytokines, thereby enhancing anti-tumor efficacy.
Career Highlights
Fangliang Zhang is associated with Nanjing Genscript Biotech Co., Ltd., where he continues to advance his research in biotechnology. His work is characterized by a strong focus on developing novel therapeutic strategies that leverage the specificity of antibodies for targeted drug delivery.
Collaborations
Fangliang Zhang has collaborated with notable colleagues, including Zhongdao Li and Lixin Song. These partnerships have contributed to the advancement of his research and the successful development of innovative biotechnological solutions.
Conclusion
Fangliang Zhang's contributions to the field of immunotherapy through his innovative fusion protein dimer represent a significant advancement in cancer treatment. His work exemplifies the potential of biotechnology to improve therapeutic outcomes for patients.